Filing Flows › Ligand Pharmaceuticals (LGND) › Q3 2026 › vs Q2 2026
Ligand Pharmaceuticals (LGND) Q3 2026 vs Q2 2026 (quarter over quarter)
Ligand Pharmaceuticals's revenue rose $15.1M (+24%) from $63.7M in Q2 2026 to $78.7M in Q3 2026.
Ligand Pharmaceuticals, Q3 2026: revenue $78.7M (-32% year over year), operating margin -20.0%, net loss $28.5M, operating cash flow −$27.6M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $78.7M | $63.7M | $15.1M | +24% |
| Income tax benefit | $15.6M | −$15.8M | $31.4M | — |
| Net loss | $28.5M | −$48.5M | $77.0M | — |
| Costs & expenses | $123M | $119M | $3.4M | +3% |
| Operating costs | $94.5M | $55.1M | $39.4M | +72% |
| Interest & other, net | $28.3M | −$55.7M | $84.0M | — |
| Research & development | $2.8M | $14.7M | −$11.9M | -81% |
| General & admin | $72.6M | $29.1M | $43.5M | +149% |
| Other operating costs | $19.1M | $11.3M | $7.8M | +69% |
| Operating cash sources | $56.1M | −$2.1M | $58.2M | — |
| Depreciation & amortization | $10.3M | $8.2M | $2.1M | +26% |
| Share-based compensation | $18.2M | $13.7M | $4.5M | +33% |
| Cash used in operations | $27.6M | −$24.0M | $51.6M | — |
| Net loss absorbed | $28.5M | −$48.5M | $77.0M | — |
| Working capital & other | $27.6M | $46.4M | −$18.7M | -40% |
Questions
How much did Ligand Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Ligand Pharmaceuticals's revenue rose $15.1M (+24%) from $63.7M in Q2 2026 to $78.7M in Q3 2026.